Optimising a rare disease clinical trial using AI
Our client needed help building and optimising a clinical trial for a new treatment that could transform the lives of people with a rare disease. Mind+Matter, an Ashfield Health company, was asked to identify and map investigator performance, optimal site locations and patient clusters.
Mind+Matter used its proprietary AI-driven model to determine the ideal patient profile characteristics, estimate patient population size, map the patient journey, identify key investigators and locate the best trial sites.
The patient, provider and site profiling was based on Mind+Matter’s proprietary Identity Graph, a unique, interconnected data repository covering all 6.2 million healthcare providers and including over 4,000 data variables.
A scoring model was also developed to rank each site and investigator based on historical performance relative to factors such as clinical trial experience, indication expertise, diagnosed patient volume, site-enrolment rate, time-to-report results and trial-design complexity.
Using this innovative approach, Mind+Matter was able to accurately identify the size of the patient population, pinpoint patient hotspots across the US and match patients with the best healthcare providers and trial sites.
A list of top sites was matched to leading investigators using in-depth analysis, based on physician expertise, location and diagnosed patient count. Mind+Matter then generated geographic ‘heat maps’ based on site data, overlaid with patients and providers within a
100-mile radius of an identified site.
From this, the client was able to identify more high-value investigators and more diagnosed patients in relation to the top 30 sites.
Discover more about EmerGENE
EmerGENE is the first multidisciplinary, global network of experts from across Ashfield and Sharp all passionately focused on the success of your cell and gene therapy.